Co-Editor-in-Chief:

editor-cheif-ijcpmh

HY Lane

Distinguished Professor, Director, Graduate Institute of Biomedical Sciences, College of Medicine, China Medial University (CMU), Taichung, Taiwan.

Director, Department of Psychiatry, College of Medicine, CMU

Ph.D., National Defense Medical Center, Taipei, Taiwan, 2000

M.D, Taipei Medical University, Taipei, Taiwan, 1987

Phone: (886)-4-22052121 ext 1855, 1074

Email: hylane@gmail.com

URL:http://gibs.cmu.edu.tw/english/faculty_clinical.html

Research Interests: Neuropsychopharmacology, Cognitive neuroscience, Precision medicine

Academic Distinctions:

Y.Z. Hsu Scientific Paper Award, Biotechnology Category, Taiwan (2006)

The 10th National Innovation Award, Taiwan (2013)

The 24th Wang-Ming-Ning Award, Taiwan (2014)

Ministry of Science and Technology Outstanding Research Award, Taiwan (2014)

CNS Drug Innovation Award, The International of College of Neuropsychopharmacology (2016)

The 14th National Innovation Award, Taiwan (2017)

Ministry of Science and Technology Outstanding Technique Transfer Award, Taiwan (2018)                                                                                                                              

Appointments:

2006-2008:      Adjunct Research Fellow, Institute of Biomedical Sciences, Academia Sinica

2007-present:  Director, Department of Psychiatry, CMU and Hospital

2009-present:  Distinguished Professor,Director, Graduate Institute of Clinical Medical Science, CMU

2016-present:  Distinguished Professor,Director, Graduate Institute of Biomedical Sciences, CMU

Research Interests:

Dr. Hsien-Yuan Lane’s research interests primarily focus on neuropsychopharmacology. In recent years, his study aims to (1) determine genetic and non-genetic determinants for treatment response of mental disorders; (2) develop novel NMDA-enhancing agents for treating mental disorders and dementia.These studies are innovative, carefully designed and likely to revolutionize our understanding and care of patients afflicted with mental disorders or dementia.

 Representative Publications:

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. Arch Gen Psychiatry. 2005Nov;62(11):1196-204.

Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.Huang CC, Wei IH, Huang CL, Chen KT, Tsai MH, Tsai P, Tun R, Huang KH, Chang YC, Lane HY*, Tsai GE.Biol Psychiatry. 2013 Nov 15;74(10):734-41.

Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, Tun R, Chang YC, Tsai GE.JAMA Psychiatry. 2013 Dec;70(12):1267-75.

Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial.Lin CH, Chen PK, Chou LJ, Chang YC, Chen YS, Tsai GE, Lane HY*.Biol Psychiatry.2014 May; 75(9):678-85.

Distinctively higher plasma G72 protein levels in patients with schizophrenia than in healthy individuals.Lin CH, Chang HT, Chen YJ, Lin CH, Huang CH, Tun R, Tsai, G, Lane HY*.Mol Psychiatry. 2014 June 19(6):636-7.

Sodium benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: arandomized, double-blind, placebo-controlled trial.Lin CH, Lin CH, Chang YC, Huang YJ, Chen PW, Yang HT, Lane HY*.Biol Psychiatry. 2018Sep 15;84(6):422-432.

Publication List:

  1. Chang WH, Hwu HG, Lane HY, Lin SK, Chen TY, Chen H, Wei HL, Lin WL, Lin HN (1991): Dose dependent reduced haloperidol/haloperidol ratios in schizophrenic patients. Psychiatry Research 38:215-225 (sci)
  2. Lane HY, Lee YJ, Lee MB, Tseng MC (1991): Behavior Therapy for trichotillomania: Report of one case. Chinese Psychiatry. 5:167-172 (in Chinese with English abstract).
  3. Chang WH, Lin SK, Juang DJ, Chen LC, Yang CH, Lane HY, Jann MW (1993): Effects of haloperidol decanoate on plasma homovanillic acid in chronic schizophrenic patients. Biological Psychiatry 33:557-559 (sci)
  4. Lane HY, Chang WH, Hwu HG, Lin HN (1994): Haloperidol metabolism and clinical implication. Chinese Psychiatry 8:137-149 (in Chinese with English abstract)
  5. Lane HY, Lin HN, Hwu HG, Jann M W, Hu WH, Chang WH (1995): Haloperidol plasma concentrations in Taiwanese psychiatric patients. Journal of the Formosan Medical Association 94：671-678 (sci)
  6. Cheng JJ, Ho H, Chang CJ, Lane HY, Hu HG (1996): Positive and negative syndrome scale (PANSS): establishment and reliability study of a mandarin Chinese language version. Chinese Psychiatry 10:251-258 (in Chinese with English abstract)
  7. Lane HY, Deng HC, Huang SM, Hu WH, Chang WH, Hu OYP (1996): Low frequency of dextromethorphan O-demethylation deficiency in a Chinese population. Clinical Pharmacology and Therapeutics 60:696-698 (sci)
  8. Chen CH, Lane HY, Chang WH (1997): Cautious on combined used of fluvoxamine and clozapine. Taiwanese Journal of Psychiatry 11:101-102 (in Chinese)
  9. Juang DJ, Chang SC, Wu ST, Lane HY, Hu WH, Chang WH (1997): Reversible metabolism of haloperidol and reduced haloperidol in Guinea Pigs. Taiwanese Journal of Psychiatry 11:48-60 (in Chinese with English abstract)
  10. Lane HY, Lin HN, Hu OYP, Chen CC, Jann MW, Chang WH (1997): Blood levels of reduced haloperidol versus clinical efficacy and extrapyramidal side effects off haloperidol. Progress in Neuro-Psychopharmacology & Biological Psychiatry 21:299-311 (sci)
  11. Lane HY, Hu OYP, Jann MW, Deng HC, Lin HN, Chang WH (1997): Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. Psychiatry Research 69:105-111 (sci)
  12. Lane HY, Chang WH, Chang YC, Hu OPY, Lin HN, Jann MW, Hu WH (1997): Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables. Psychiatry Research 72:127-132 (sci)
  13. Chang WH, Lin SK, Lane HY, Hu WH, Jann MW, Lin HN (1997): Clozapine dosages and plasma drug concentrations. Journal of the Formosan Medical Association 96:599-605 (sci)
  14. Lane HY, Chang WH (1997): The role of the cytochrome P450 system in the metabolism of psychotropic drugs. Taiwanese Journal of Psychiatry 11:345-356
  15. Lane HY, Chang WH, Chou JCY (1998): Seizure during risperidone treatment in an elderly woman treated with concomitant medications. The Journal of Clinical Psychiatry 59:81-82 (sci)
  16. Lane HY, Lin YC, Chang WH (1998): Mania induced by risperidone: dose related? The Journal of Clinical Psychiatry 59:85-86 (sci)
  17. Lane HY, Su KP, Chang WH, Jann MW (1998): Elevated plasma clozapine concentrations after phenobarbital discontinuation. The Journal of Clinical Psychiatry 59:131-133 (sci)
  18. Kuo FJ, Lane HY, Chang WH (1998): Extrapyramidal symptoms following addition of fluvoxamine to clozapine. Journal of Clinical Psychopharmacology 18:483-484 (sci)
  19. Hu OYP, Tang HS, Lane HY, Chang WH,Hu TM (1998): Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity. The Journal of Pharmacology and Experimental Therapeutics 285: 955-960 (sci)
  20. Chiu CC, Lane HY, Liu HC, Chen CH, Jann MW, Chang WH (1998): Pharmacokinetics of clozapine, desmethylclozapine and clozapine-N-oxide in Taiwanese schizophrenic patients. Taiwanese Journal of Psychiatry 12: 27-35 (in Chinese with English abstract)
  21. Chang WH, Lin SK, Lane HY, Wei FC, Lam YF, Jann MW (1998): Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. Progress in Neuro-Psychopharmacology & Biological Psychiatry 22:723-739 (sci)
  22. Lane HY, Chang WH (1998): Risperidone–carbamazepine interactions: cytochrome P450 3A involved? The Journal of Clinical Psychiatry 59: 430-431 (sci)
  23. Lane HY, Chang WH (1998): Manic and psychotic symptoms following risperidone withdrawal in a schizophrenic patient. The Journal of Clinical Psychiatry 59: 620-621 (sci)
  24. Lane HY, Chang WH (1998): Risperidone monotherapy for psychotic depression unresponsive to other treatments. The Journal of Clinical Psychiatry 59: 624 (sci)
  25. Chen CH, Lane HY, Liu HC, Chiu CC, Chen WZ, Chang WH (1998): Effects of fluvoxamine on clozapine pharmacokinetics. Taiwanese Journal of Psychiatry 12: 150-156 (in Chinese with English abstract)
  26. Lu ML, Peng SL, Lane HY* (1998): Clozapine withdrawal. Taiwanese Journal of Psychiatry 12: 170-172 (in Chinese with English abstract) [*corresponding author]
  27. Lane HY, Chang YC, Chang WH, Lin SK, Tseng YT, Jann MW (1999): Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. The Journal of Clinical Psychiatry 60:36-40 (sci)
  28. Lane HY, Liu CC, Chang WH (1999): Risperidone for exclusively negative symptoms. The American Journal of Psychiatry 156:335 (sci)
  29. Lane HY, Su KP, Chang WH (1999): Seizures after withdrawal of low-dose lorazepam: precipitated by an originally seizure-free clozapine regimen? The Journal of Clinical Psychiatry 60:408-409 (sci)
  30. Lane HY, Chang WH (1999): Clozapine versus risperidone in treatment-refractory schizophrenia: possible impact of dosing strategies. Journal of Clinical Psychiatry 60:487-488 (sci)
  31. Lane HY, Chiu WC, Chang WH (1999): Risperidone monotherapy for mania and depression. The American Journal of Psychiatry 156:1115 (sci)
  32. Lu ML, Lane HY, Chang WH (1999): Selective serotonin reuptake inhibitor discontinuation syndrome: precipitated by concomitant clozapine? Journal of Clinical Psychopharmacology 19:386-387 (sci)
  33. Chang WH, Augustin B, Lane HY, ZumBrunnen T, Liu HC, Kazmi Y, Jann MW (1999): In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine. Psychopharmacology 145:91-98 (sci)
  34. Chiu WC, Lane HY, Lee SH, Chen CC, Hu WH, Chang WH (1999): Fixed and low doses of risperidone in the treatment of acutely exacerbated schizophrenic patients. Taiwanese Journal of Psychiatry 13:201-208 (in Chinese with English abstract)
  35. Chen KP, Lu ML, Lane HY, Chang WH (1999): Effects of concomitant fluvoxamine on steady-state plasma clozapine concentrations in schizophrenia patients. Taiwanese Journal of Psychiatry 13:219-227 (in Chinese with English abstract)
  36. Lane HY, Chiu WC, Chou JCY, Wu ST, Su MH, Chang WH (2000): Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. Journal of Clinical Psychiatry 61:209-214 (sci)
  37. Chou JCY, Czobor P, Tuma I, Charles O, Bebe R, Cooper TB, Chang WH, Lane HY, Stone DL (2000): Pretreatment plasma HVA and haloperidol response in acute mania. Journal of Affective Disorders 59:55-59 (sci)
  38. Lu ML, Lane HY, Chen KP, Jann MW, Su MH, Chang WH (2000): Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. Journal of Clinical Psychiatry 61:594-599 (sci)
  39. Lane HY, Liu HC, VanDenBerg CM, Su MH, Jann MW, Chang WH (2000): Disposition of olanzapine in Chinese schizophrenic patients. International Journal of Clinical Pharmacology and therapeutics 38:482-485 (sci)
  40. Lane HY, Jann MW, Chang YC, Chiu CC, Huang MC, Chang WH (2001): Repeated ingestion of grapefruit juice does not alter clozapine’s steady-state plasma levels, effectiveness, and tolerability. Journal of Clinical Psychiatry 62: 812-817 (sci)
  41. Lane HY, Chiu CC, Kazmi Y, Desai H, Lam YWF, Jann MW, Chang WH (2001): Lack of interaction between grapefruit juice and ketoconazole with single clozapine dose in schizophrenic patients. Drug Metabolism and Drug Interactions 18:263-278
  42. Lu ML, Lane HY*, Chang WH (2001). Differences between in vitro and in vivo determinations of fluvoxamine-clozapine interaction. Journal of Clinical Psychophramacology 21:625-626 (sci)[*corresponding author]
  43. Jann MW, Chang WH, Lane HY (2001). Differences in haloperidol epidemiologic pharmacokinetic studies. Journal of Clinical Psychophramacology 21:628-630 (sci)
  44. Lane HY, Chang WH, Chiu CC, Huang MC, Lee SH, Chen JY (2001): A pilot double-blind, dose-comparison study of risperidone in drug-naive, first-episode schizophrenia. Journal of Clinical Psychiatry 62:994-995 (sci)
  45. Lu ML, Lane HY, Chang WH (2001): Comment: unanticipated plasma concentrations in two clozapine-treated patients. The Annals of Pharmacotherapy 35:1679-1680 (sci)
  46. Lane HY, Chang YC, Su MH, Chiu CC, Huang MC, Chang WH (2002). Shifting from haloperidol to risperidone for psychosis and behavioral disturbances in dementia: safety, efficacy, response predictors, and mood effects. Journal of Clinical Psychopharmacology 22:4-10 (sci)
  47. Lane HY, Cheng KN, Chang SL, Hsiao YT, Lu HC (2002): Correlation of two widely used psychiatric rating scales in patients with schizophrenia. Tzu-Chi Med J 14:213-218
  48. Lane HY, Chang YC, Chiu CC, Chen TT, Lee SH, Chang WH (2002). Influences of patient-related variables on risperidone efficacy for acutely exacerbated schizophrenia: analyses with rigorous statistics. Journal of Clinical Psychopharmacology 22:353-358 (sci)
  49. Lu ML, Lane HY*, Chang WH (2002): Fluvoxamine-clozapine interaction: time-dependent? Journal of Clinical Psychopharmacology 22:439-440 (sci) [*corresponding author]
  50. Lane HY, Chang YC, Chiu CC, Chen ML, Hsieh MH, Chang WH (2002): Association of risperidone treatment response with a polymorphism in the 5-HT2Areceptor gene. The American Journal of Psychiatry 159:1593-1595 (sci)
  51. Lane HY, Guo SC, Hwang TJ, Chen YS, Cheng JJ, Lee YC, Hong CJ, Hwu HG, Chang WH (2002): Olanzapine plasma levels and antidepressant effects in schizophrenic patients. Journal of Clinical Psychopharmacology 22:530-532 (sci)
  52. Lu ML, Lane HY*, Chang WH (2002): Dosing strategies of clozapine-fluvoxamine cotreatment. Journal of Clinical Psychopharmacology 22:626-628 (sci) [*corresponding author]
  53. Chang CJ, Chen WJ, Liu SK, Cheng JJ, Yang WC, Chang HJ, Lane HY, Lin SK, Yang TW, Hwu HG (2002): Morbidity risk of psychiatric disorders among the first degree relatives of schizophrenia patients in Taiwan. Schizophr Bull 28:379-392 (sci).
  54. Lu ML, Lane HY* (2003): Adjunctive fluvoxamine with clozapine. The British Journal of Psychiatry 182:81 (sci) [*corresponding author]
  55. Lane HY, Chang YC, Cheng YC, Liu GC, Lin XR, Chang WH (2003): Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia patients. Journal of Clinical Psychiatry 64:316-320 (sci)
  56. Lane HY, Leu TD, Chang WH (2003): Schizophrenia: attention deficits and the NMDA hypothesis. Tzu-Chi Med J 15:141-148
  57. Lane HY, Hung CH, Chang WH (2003): Genetic factors influencing cognitive function. Acta NeurologicaTaiwanica 12:114-122
  58. Lane HY, Chang YC, Huang CL, Chang WH (2003): Refining pharmacogenetic research in schizophrenia: control for patient-related variables. Drug Development Research 60:164-171 (sci)
  59. Lane HY, Chang YC, Chiu CC, Lee SH, Lin CY, Chang WH (2004): Fine-tuning risperidone dosage for acute schizophrenia: clinical determinants Psychopharmacology 172:393-399 (sci)
  60. Su KP, Lane HY, Chuang CL, Chen KP, Shen WW (2004): Olanzapine-induced QTc prolongation in a patient with Wolff-Parkinson-White syndrome. Schizophrenia Research 66:191-192 (sci)
  61. Lane HY, Lin CC, Huang CH, Chang YC, Hsu SK, Chang WH (2004): Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders. Schizophrenia Research 67:63-70 (sci)
  62. Lane HY, Huang CL, Lin CY, Chang WH (2004): NMDA modulation and schizophrenia. Current Topics in Pharmacology 8:305-312
  63. Tsai G, Lane HY*, Yang P, Chong MY, Lange N (2004): Glycine transporter I inhibitor, N-methylglycine (sarcosine) added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry 55:452-456 (sci) [*shared first author]
  64. Lu ML, Lane HY*, Lin SK, Chen KP, Chang WH (2004): Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. Journal of Clinical Psychiatry 65: 766-771 (sci) [*corresponding author]
  65. Lane HY, Lee CC, Chang YC, Lu CT, Huang CH, Chang WH (2004): Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. International Journal of Neuropsychopharmacology 7:461-470 (sci)
  66. Chiu CC, Lane HY, Huang MC, Liu HC, Jann MW, HonYY, Chang WH, Lu ML (2004): Dose-dependent alternations in oral bioavailability and clearance of olanzapine during coadministration of fluvoxamine in schizophrenic patients. Journal of Clinical Pharmacology 44: 1385-1390 (sci)
  67. Lane HY, Hsu SK, Liu YC, Chang YC, Huang CH, Chang WH (2005): Dopamine D3 receptor Ser9Gly polymorphism and risperidone response: a rigorous pharmacogenetic study. Journal of Clinical Psychopharmacology 25:6-11 (sci)
  68. Sun HS, Fann CSJ, Lane HY, Chang YT, Chang CJ, Liu YL, Cheng ATA (2005). A functional polymorphism in the promoter region of the tryptophan hydroxylase (TPH1) gene is associated with alcohol dependence in one aboriginal group in Taiwan. Alcoholism: Clinical and Experimental Research 29:1-7 (sci)
  69. Lane HY, Lee CC, Liu YC, Chang WH (2005): Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics. Pharmacogenomics 6:139-149 (sci)
  70. Chiu CC, Lane HY*, Huang MC, Liu HC, Jann MW, HonYY, Chang WH, Lu ML (2005): Regular-dose risperidone on QTc intervals. Journal of Clinical Psychopharmacology 25:391-393 (sci) [*corresponding author]
  71. Chen CM, Lane HY*, Wu YR, Ro LS, Chen FL, Hung WL, Hou YT, Lin CY, Huang SY, Chen I C, Soong BW, Li ML, Hsieh-Li HM, Su MT, Lee-Chen GJ (2005): Expanded trinucleotide repeats in the TBP/SCA17 gene, but not the KLHL1AS/SCA8 and PPP2R2B/SCA12 genes, are associated with schizophrenia. Schizophrenia Research 78:131-136 (sci) [*corresponding author]
  72. Lane HY, Chang YC, Liu YC, Chiu CC, Tsai G (2005): Sarcosine (N-methylglycine) or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Archives of General Psychiatry 62:1196-1204 (sci)
  73. Hsieh CL, Chang QY, Lin IH, Lin JG, Liu CH, Tang NY, Lane HY* (2006): The study of electroacupuncture on cerebral blood flow in rats with and without cerebral ischemia. American Journal of Chinese Medicine 34:351-361 (sci) [*corresponding author]
  74. Lane HY, Liu YC, Huang CL, Chang YC, Wu PL, Lu CT, Chang WH (2006): Risperidone-related weight gain: genetic and nongenetic predictors. Journal of Clinical Psychopharmacology 26:128-134 (sci)
  75. Lane HY, Huang CL, Wu PL, Liu YC, Chang YC, Lin PY, Chen PW, Tsai G (2006): Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biological Psychiatry 60:645-649 (sci)
  76. Loh EW, Lane HY, Chen CH, Chang PS, Ku LW, Wang KHZ, Cheng ATA (2006): Glutamate decarboxylase genes and alcoholism in Han Taiwanese men. Alcoholism: Clinical and Experimental Research 30:1817-1823 (sci)
  77. Chang YC, Lane HY, Yang KH, Huang CL (2006): Optimizing early prediction for antipsychotic response in schizophrenia. Journal of Clinical Psychopharmacology 26:554-559 (sci)
  78. Lin CH, Chou LS, Lin CH, Hsu CY, Chen YS, Lane HY* (2007): Early prediction of clinical response in schizophrenia patients receiving atypical antipsychotic zotepine. The Journal of Clinical Psychiatry 68:1522-1527 (sci) [*corresponding author]
  79. Lane HY, Liu YC, Huang CL, Hsieh CL, Chang YL, Chang L, Chang YC, Chang WH (2008): Prefrontal executive function and D1, D3, 5-HT2A, and 5-HT6 receptors gene variations in healthy participants. Journal of Psychiatry and Neuroscience 33:47-53 (sci)
  80. Lin CH, Lin KS, Lin CY, Chen MC, Lane HY* (2008): Time to rehospitalization in major depression patients taking venlafaxine or fluoxetine. The Journal of Clinical Psychiatry 69:54-59 (sci) [*corresponding author]
  81. Lin YC, Chen HZ, Chang TJ, Lane HY* (2008): Hypokalemia following rapid titration of quetiapine treatment. The Journal of Clinical Psychiatry 69:165-166 (sci) [*corresponding author]
  82. Lane HY, Liu YC, Huang CL, Chang YC, Wu PL, Huang CH, Tsai G (2008): RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia. Journal of Clinical Psychopharmacology 28:64-68 (sci)
  83. Tsai GE, Lane HY*, VanDenBerg CM, Liu YC, Tsai P, Jann MW (2008): Disposition of D-serine in Healthy Adults. The Journal of Clinical Pharmacology 48:524-527 (sci) [*shared first author]
  84. Lane HY, Liu YC, Huang CL, Chang YC, Liau CH, Tsai G (2008): Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biological Psychiatry 63:9-12 (sci) (selected for the commentary article)
  85. Lin CH, Huang CW, Chen CC, Hsu YF, Chang WH, Lane HY* (2008): Time to rehospitalization in patients with bipolar I disorder on lithium or valproate with adjunctive antipsychotics. Psychopharmacology 200: 301-303 (sci) [*corresponding author]
  86. Ma WF, Lane HY, Laffrey SC (2008): A model testing factors that influence physical activity for Taiwanese adults with anxiety. Research in Nursing and Health 31: 476-489 (sci)
  87. Lin YC, Su HK, Ouyang WC, Lane HY* (2008): Zotepine-Induced QTc prolongation. Journal of Clinical Psychopharmacology 28:576-578 [*corresponding author]
  88. Chen CM, Hou YT, Liu JY, Wu YR, Lin CH, Fung HC, Hsu WC, Hsu Y, Lee SH, Hsieh-Li HM, Su MT, Chen ST, Lane HY, Lee-Chen GJ (2009): PPP2R2B CAG repeat length in the Han Chinese in Taiwan: Association analyses in neurological and psychiatric disorders and potential functional implications. Am J Med Genet B Neuropsychiatr Genet. 150B:124-129 (sci)
  89. Liu YC,Huang CL, Wu PL, Chang YC, Huang CH, Lane HY* (2009): Lack of association between AKT1 variances vs. clinical manifestations and social function in patients with schizophrenia. Journal of Psychopharmacology 23:937-943 [*corresponding author]
  90. Ma WF, Yen JW, Chen WC, Chang HJ, Huang XY, Lane HY* (2009). The roles of state and trait anxiety in physical activity participation for Taiwanese adults with anxiety disorders. Journal of Formosa Medical Association. 108(6), 481-492. [*corresponding authors]
  91. Chang JP, Tsai CH, Wu PL, Lane HY, Su KP (2009): Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) treatment for Isaacs syndrome with depression. Prog Neuropsychopharmacol Biol Psychiatry. 33: 739-740.
  92. Chang YC, Lane HY (2009): Reply to Comments on “Optimizing early prediction for antipsychotic response in schizophrenia. Journal of Clinical Psychopharmacology 29: 391.
  93. Huang YJ, Lane HY, Liao CH, Huang CC (2009): Recurrent pancreatitis without eosinophilia on clozapine rechallenge. Progress in Neuro-Psychopharmacology & Biological Psychiatry 33: 1561-1562.
  94. Lane HY, Lin C-H, Huang CL, Chang YC, Liau CH, Tsai GE (2010): A Randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. International Journal of Neuropsychopharmacology 13:451-460 (sci)
  95. Lo CH, Tsai G, Lioa CH, Wang MY, Chang JPC, Tsuang HC, Lane HY* (2010): Emotional management and 5-HT2A receptor gene variance in patients with schizophrenia. Biological Psychology 83:79-83 [*corresponding author]
  96. Lane HY, Tsai GE, Lin E (2010): The serotonin transporter gene-linked polymorphic region (5-HTTLPR) in recent research on pharmacogenomics and disease susceptibility. Personalized Medicine 7: 139-141.
  97. Lin CH, Chen MC, Chou LS, Lin CH, Chen CC, Lane HY* (2010): Time to rehospitalization in patients with major depression vs. those with schizophrenia or bipolar I disorder in a public psychiatric hospital. Psychiatric Research 180: 74-79 [*corresponding author]
  98. Ma WF, Tsai GE, Chang JP, Lane HY* (2010): Reliability and validity of three Chinese version tasks of Mayer-Salovey-Caruso Emotional Intelligence Test. J Clin Nursing 19;2656-2658 [*corresponding author]
  99. Ma WF, Wu PL, Yang SJ, Cheng KF, Chiu HT, Lane HY (2010): Sensitivity and specificity of the Chinese version of the Schizotypal Personality Questionnaire-Brief for identifying undergraduate students susceptible to psychosis. International Journal of Nursing Studies 47:1535-1544.
  100. Lin CH, Hsu CW, Lin CH, Lane HY* (2010): Mirtazapine-associated hair loss. The Journal of Clinical Psychiatry 71:1400-1401 [*corresponding author]
  101. Lin CH, Kuo CC, Chou LS, Chen YH, Chen CC, Huang KH, Lane HY* (2010): A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia. Journal of Clinical Psychopharmacology 30: 518-525 [*corresponding author]
  102. Tseng YL, Chiang ML, Huang TF, Su KP, Lane HY, Lai YC (2010): A selective serotonin reuptake inhibitor, citalopram, inhibits collagen-induced platelet aggregation and activation. Thrombosis Research 126:517-523.
  103. Liao CH, Chang CS, Wei WC, Chang SN, Liao CC, Lane HY, Sung FC (2011): Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population based study. Schizophrenia Research 126:110-116.
  104. Lin CH, Lane HY, Chen CC, Juo SHH, Yen CF (2011): Early prediction of fluoxetine response for Han-Chinese inpatients with major depressive disorder. Journal of Clinical Psychopharmacology 31: 187-193.
  105. Lee MTM, Chen CH, Lee CS, Chen CC, Chong MY, Ouyang WC, Chiu NY, Chuo LJ, Chen CY, Tan HKL, Lane HY, Chang TJ, Lin CH,JouSH, Hou YM, Feng J, Lai TJ, Tung CL, Chen TJ, Chang CJ, Lung FW, Chen CK, Shiah IS, Liu CY, Teng PR, Chen KH, Shen LJ, Cheng CS, Chang TP, Li CF, Chou CH, Chen CY, Wang KHT, Fann CSJ, Wu JY, Chen YT, Cheng ATA (2011): Genome-wide Association study of bipolar I disorder in the Han Chinese population. Molecular Psychiatry 16:548-556
  106. Wu PL, Tang HS, Lane HY, Tsai CA, Tsai GE (2011): Sarcosine therapy for obsessive compulsive disorder: a prospective, open-label study. Journal of Clinical Psychopharmacology 31:369-374
  107. Lin CH, Lane HY* (2011): Reply to comments by Dr. Suzuki on “A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia”. J Clin Psychopharmacol 31:399-400 [*corresponding author].
  108. Chen PK, Fuh JL, Lane HY, Chiu PY, Tien HC, Wang SJ (2011): Morning headache in habitual snorers: Frequency, characteristics, predictors and impacts. Cephalalgia. 31:829-836.
  109. Lin CH, Lane HY, Chen CC, Juo SH, Yen CF (2011): Predictors of fluoxetine remission for hospitalized patients with major depressive disorder. Psychiatry Clin Neurosci. 65:510-517.
  110. Liao CH, Chang CS, Chang SN, Lane HY, Lyu SY, Morisky DE, Sung FC (2011): The risk of temporomandibular disorder in patients with depression: a population-based cohort study. Community Dent Oral Epidemiol. 39:525-531.
  111. Lin CH, Lane HY, Chen CC, Juo SHH, Yen CF (2011): Pain has a strong negative impact on the fluoxetine response in hospitalized patients with major depressive disorder. The Clinical Journal of Pain 27:805-810.
  112. Hung CC, Chiou MH, Huang BH, Hsieh YW, Hsieh TJ, Huang CL, Lane HY* (2011): Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics 12:1525-1533 [*corresponding author]
  113. Su CH, Liu LC, Hsieh YH, Wang HC, Tsai CW, Chang WS, Ho CY, Wu CI, Lin CH, Lane HY, Bau DT (2011): Association of Alpha B-Crystallin (CRYAB) Genotypes with breast cancer susceptibility in Taiwan. Cancer Genomics Proteomics. 8:251-254.
  114. Liu LC, Su CH, Wang HC, Tsai CW, Chang WS, Ho CY, Wu CI, Li FJ, Lin CH, Lane HY, Bau DT (2011): Significant Association of Caveolin-1 (CAV1) Genotypes with breast cancer in Taiwan. Anticancer Research. 31:3511-3515.
  115. Chen HY, Chang YC, Lane HY (2011): Correlation in retinal nerve fiber layer thickness between two OCT units. Optometry and Vision Science 88:1326-1332.
  116. Ten P, Lane HY* (2011): Emergence of neuroleptic malignant syndrome while switching between risperidone and paliperidone. The Journal of Neuropsychiatry and Clinical Neurosciences 23(4):E16-7. [*corresponding author]
  117. Lin CH, Lane HY, Tsai GE (2012): Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacology, Biochemistry and Behavior 100:665-677.
  118. Yeh CC, Liao CC, Muo CH, Chang SN, Hsieh CH, Chen FN, Lane HY, Sung FC (2012): Mental disorder as a risk factor for dog bites and post-bite cellulitis. Injury 43:1903-1907.
  119. Chang KC, Huang CL, Liang HY, Chang SS, Wang YC, Liang WM, Lane HY, Chen CH, Stephen Huang SK (2012): Differences in susceptibility to low-dose methadone-associated QTc prolongation in patients with heroin dependence. Journal of Cardiovascular Electrophysiology 23:527-533.
  120. Lane HY, Tsai G, Lin E (2012): Rapid antidepressant effects of ketamine on circadian gene expression. Personalized Medicine 9(1): 15-16.
  121. Lane HY, Tsai G, Lin E (2012): Assessing gene-gene interactions in pharmacogenomics. Molecular Diagnosis & Therapy Feb 1;16(1):15-27. doi: 10.2165/11597270-000000000-00000
  122. Lin CH, Huang KH, Chang YC, Huang YC, Hsu WC, Lin CY, Chou FHC, Tsi GE, Lane HY* (2012): Clozapine protects bone mineral density in female patients with schizophrenia. International Journal of Neuropsychopharmacology 15:897-906 [*corresponding author]
  123. Huang YJ, Lin CH, Lane HY, Tsai G (2012): NMDA neurotransmission dysfunction in behavioral and psychological symptoms of Alzheimer’s disease. Current Neuropharmacology 10(3):272-285.
  124. Wu PL, Lane HY, Tang HS, Tsai GE (2012). Glutamate theory in developing novel pharmacotherapies for obsessive compulsive disorder: Focusing on N-methyl-D-aspartate signaling. BioMedicine, 2 (2): 75-79.
  125. Chang HJ, Lane HY, Tsai GE (2012): The hypothesis of NMDA receptor hypofunction for schizophrenia. Taiwanese Journal of Psychiatry 26:147-161.
  126. Lai CH, Lane HY, Tsai G(2012): Clinical and cerebral volumetric effects of sodium benzoate, a D-amino acid oxidase inhibitor, in a drug-naive patient with major depression. Biological Psychiatry 71(4):e9-e10.
  127. Lin MT, Huang KH, Huang CL, Huang YJ, Tsai G, Lane HY* (2012): MET and AKT genetic influence on facial emotion perception. PLoS ONE 7(4): e36143. doi:10.1371/journal.pone.0036143 [*corresponding author]
  128. Lin CH, Chou LS, Lin CH, Hsu, CY, Chen CC, Lane HY* (2012): Optimizing the early prediction model for symptomatic remission with short-term treatment for schizophrenia. Journal of Clinical Psychopharmacology Dec;32(6):773-7. doi: 10.1097/JCP.0b013e318270dfca.. [*corresponding author]
  129. Ma WF, Liu YC, Chen YF, Lane HY, Lai TJ, Huang LC (2012): Evaluation of psychometric properties of the Chinese mandarin version State-Trait Anxiety Inventory Y form in Taiwanese outpatients with anxiety disorders. Journal of Psychiatric and Mental Health Nursing 20(6):499-507
  130. Tsuang HC, Chen WJ, Lin SH, Chen TY, Chang TL, Huang KH, Lane HY* (2013): Impaired impulse control is associated with a 5-HT2A receptor polymorphism in schizophrenia. Psychiatry Research 208(2): 105-110 [*corresponding author]
  131. Lin CY, Lane HY, Chen TT, Wu YH, Wu CY, Wu VY (2013): Inverse association between cancer risks and age in schizophrenic patients: A 12-year nationwide cohort study. Cancer Science 104(3):383-90.
  132. Chen HY, Chang YC, Chen WC, Lane HY (2013): Association between plasma endothelin-1 and severity of different types of glaucoma. Journal of Glaucoma 22(2):117-22. doi: 10.1097/IJG.0b013e31822e8c65.
  133. Lin CH, Huang CL, Chang YC, Chen PW, Lin CY, Tsai GE, Lane HY* (2013): Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia. Schizophrenia Research 146(1-3):231-7 [*corresponding author]
  134. Lin CH, Chen CC, Wang FC, Lane HY* (2013): Percentage reduction of depression severity versus absolute severity after initial weeks of treatment to predict final response or remission. Psychiatry and Clinical Neurosciences 67:265-272. [*corresponding author]
  135. Lin CH, Chen, MC. Lee WK, Chen CC, Huang CH, Lane HY*(2013): ECT improves clinical manifestation with plasma BDNF levels unchanged in treatment-resistant depression patients. Neuropsychobiology. 68:110-115. [*corresponding author]
  136. Lin CH, Wang FC, Lin SC, Huang YH, Chen CC, Lane HY* (2013): Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study.International Clinical Psychopharmacology 28:267-274 [*corresponding author]
  137. Lin CH, Tseng YL, Huang CL, Chang YC, Tsai GE, Lane HY* (2013): Synergistic effects of COMT and TPH2 on social cognition. Psychiatry: Interpersonal and Biological Processes 76(3):273-294. [*corresponding author]
  138. Hung CC, Chiou MH, Teng UN, Hsieh YW, Huang CL, Lane HY* (2013): Functional impact of ABCB1 variants on interaction between P-glycoprotein and methadone. PLoS One 8(3):e59419. doi: 10.1371/journal.pone.0059419. Epub 2013 Mar 19. [*corresponding author]
  139. Huang CC, Wei IH, Huang CL, Chen KT, Tsai MH, Tsai P, Tun R, Huang KH, Chang YC, Lane HY*, Tsai G (2013): Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biological Psychiatry Nov 15;74(10):734-41. doi: 10.1016/j.biopsych.2013.02.020. Epub2013Apr 3.. [*corresponding author]
  140. Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, Tun R, Chang YC, Tsai GE (2013): Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry 70(12) 1267-1275.
  141. Chang SL, Hsieh CH, Chen YJ, Wang CM, Shih CS, Huang PW, Mir A, Lane HY, Tsai GE, Chang HT (2013):. The C-Terminal Region of G72 Increases d-Amino Acid Oxidase Activity. Int J Mol Sci. Dec 20;15(1):29-43. doi: 10.3390/ijms15010029.
  142. Chen CH, Lee CS, Lee MT, Ouyang WC, Chen CC, Chong MY, Wu JY, Tan HK, Lee YC, Chuo LJ, Chiu NY, Tsang HY, Chang TJ, Lung FW, Chiu CH, Chang CH, Chen YS, Hou YM, Chen CC, Lai TJ, Tung CL, Chen CY, Lane HY, Su TP, Feng J, Lin JJ, Chang CJ, Teng PR, Liu CY, Chen CK, Liu IC, Chen JJ, Lu T, Fan CC, Wu CK, Li CF, Wang KH, Wu LS, Peng HL, Chang CP, Lu LS, Chen YT, Cheng AT; Taiwan Bipolar Consortium (2014): Variant GADL1 and response to lithium therapy in bipolar I disorder. N Engl J Med. 370(2):119-28.
  143. Lee CH, Chiang SL, Ko AM, Hua CH, Tsai MH, Warnakulasuriya S, Ibrahim SO, Sunarjo, Zain RB, Ling TY, Huang CL, Lane HY, Lin CC, Ko YC (2014): Betel-quid dependence domains and syndrome associated with betel-quid ingredients among chewers: an Asian multi-country evidence. Addiction Jul;109(7):1194-204 doi: 10.1111/add.12530. Epub 2014 Apr 14.
  144. Chang JP, Lane HY, Tsai GE (2014): Attention deficit hyperactivity disorder and N-methyl-D-aspartate (NMDA) dysregulation. Current Pharmaceutical Design 2014 20(32):5180-5185.
  145. Lin CH, Huang YJ, Lane HY, Tsai GE (2104): NMDA Neurotransmission dysfunction in mild cognitive impairment and Alzheimer’s Disease. Current Pharmaceutical Design 20(32): 5169-5179.
  146. Lin CY, Tsai GE, Lane HY* (2014): Assessing and treating cognitive impairments in schizophrenia: current and future. Curr Pharm Des. 20(32):5127-5138 [*corresponding author]
  147. Chang HJ, Lane HY*, Tsai GE (2014): NMDA Pathology and treatment of schizophrenia. Current Pharmaceutical Design 20(32):5118-5126 [*corresponding author]
  148. Tsai CH, Huang HC, Liu BL, Li CI, Lu MK, Chen X, Tsai MC, Yang YW, Lane HY (2014): Activation of N-methyl-D-aspartate receptor glycine site temporally ameliorates neuropsychiatric symptoms of Parkinson’s disease with dementia. Psychiatry and Clinical Neurosciences Sep;68(9):692-700. doi: 10.1111/pcn.12175. Epub 2014 Apr 14.
  149. Chuang LY, Lane HY, Lin YD, Lin MT, Yang CH, Chang HW (2014): Identification of SNP barcode biomarkers for genes associated with facial emotion perception using particle swarm optimization algorithm. Ann Gen Psychiatry. 2014 May 21;13:15. doi: 10.1186/1744-859X-13-15. eCollection 2014.
  150. Lin CY, Tsai G. Wang HS, Wu YH, Chiou CC, Wu VY, Lane HY* (2014): Effectiveness of Aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study. J Clin Psychiatry 75(9):e924-31. [*corresponding author]
  151. Lin JH, Huang MW, Wang DW, Chen YM, Lin CS, Tang YJ, Yang SH, Lane HY* (2014): Late-life depression and quality of life in a geriatric evaluation and management unit: an exploratory study. BMC Geriatrics. 2014 Jun 18;14:77. doi: 10.1186/1471-2318-14-77.
  152. Lin CH, Chen PK, Chou LJ, Chang YC, Chen YS, Tsai GE, Lane HY* (2014): Benzoate, a D-amino acid oxidase inhibitor, for treatment of early-phase Alzheimer’s disease: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry 75(9):678-85 [*corresponding author]
  153. Lin CH, Chang HT, Chen YJ, Lin CH, Huang CH, Tun R, Tsai, G, Lane HY* (2014): Distinctively higher plasma G72 protein levels in patients with schizophrenia than in healthy individuals. Molecular Psychiatry 19(6):636-7. doi: 10.1038/mp.2013.80. Epub 2013 Jul 16. [*corresponding author]
  154. Chen YT, Huang MW, Hung IC, Lane HY, Hou CJ (2014): Right and left amygdalae activation in patients with major depression receiving antidepressant treatment, as revealed by fMRI.Behav Brain Funct. Oct 8;10(1):36. doi: 10.1186/1744-9081-10-36.
  155. Lin E, Lane HY* (2014): Highlights from the latest articles in pharmacogenomics of antipsychotics. Pharmacogenomics. 15(4): 415-7. [*corresponding author]
  156. Ma WF, Lane HY, Chiang LC, Wu PL, Yang SJ, Tsai GE (2015): Assessing the construct validity of the Chinese-version Schizotypal Personality Questionnaire-Brief on male and female undergraduate students. J Nurs Res. 2015 Jun;23(2):162-6.
  157. Hsu WY, Lane HY, Lin CL, Kao CH (2015): A population-based cohort study on deep vein thrombosis and pulmonary embolism among schizophrenia patients. Schizophr Res. 2015 Mar;162(1-3):248-52.
  158. Lin CH, Lin CY, Huang TL, Wang HS, Chang YC, Lane HY* (2015): Sex-specific factors for bone density in patients with schizophrenia. Int Clin Psychopharmacol. 2015 Mar;30(2):96-102. [*corresponding author]
  159. Wu YS, Lane HY, Lin CH (2015): Donepezil improved cognitive deficits in a patient with Neurosyphilis. Clin Neuropharmacol. 2015 Jul-Aug;38(4):156-7.
  160. Chen VC, Liao YT, Lai TJ, Lane HY, Shao WC, Dewey M, Lee CT, Lu ML. Survival analysis of the use of first and second generation antipsychotics among patients suffering schizophrenia: A nationwide population-based cohort study. Schizophr Res. 2015 Oct 15. pii: S0920-9964(15)30005-0. doi: 10.1016/j.schres.2015.10.005. [Epub ahead of print]
  161. Lin E, Lane HY* (2015): Pharmacogenomics studies of antidepressants. Pharmacogenomics. Apr;16(5):555-66. [*corresponding author]
  162. Lu YY, Lin CH, Lane HY* (2016): Mania following ketamine abuse. Neuropsychiatric Disease and Treatment. Jan 27;12:237-9. doi: 10.2147/NDT.S97696. eCollection 2016
  163. Lin CH, Yang WC, Chen MC, Lane HY* (2016): Early improvement predicts outcome of major depressive patients treated with electroconvulsive therapy. European Neuropsychopharmacology Feb;26(2):225-33 [*corresponding author]
  164. Mao WC, Chen LF, Chi CH, Lin CH, Kao YC, Hsu WY, Lane HY, Hsieh JC (2016). Traditional Chinese version of the Mayer Salovey Caruso Emotional Intelligence Test (MSCEIT-TC): Its validation and application to schizophrenic individuals. Psychiatry Res. 2016 Sep 30;243:61-70.
  165. Lin PC, Lane HY, Lin CH (2016): Spontaneous remission of ketamine withdrawal-related depression. Clin Neuropharmacol. 39(1):51-2. doi: 10.1097/WNF.0000000000000121.
  166. Chen PH, Lane HY, Lin CH (2016): Venous thromboembolism following dantrolene treatment for neuroleptic malignant syndrome. Clin PsychopharmacolNeurosci. Nov 30;14(4):399-401.
  167. Chen CY, Lane HY, Lin CH. Effects of antipsychotics on bone mineral density in patients with schizophrenia: gender differences. Clin PsychopharmacolNeurosci. 2016 Aug 31;14(3):238-49.
  168. Galling B, Roldán A, Nielsen RE, Nielsen J, Gerhard T, Carbon M, Stubbs B, Vancampfort D, Hert MD, Olfson M, Kahl KG, Martin A, Jeff, Lane HY, Sung FC, Liao CH, Arango C, Correll CU (2016): Type 2 Diabetes in youth exposed to antipsychotics: a systematic review, meta-analysis and exploratory metaregression analysis. JAMA Psychiatry Mar;73(3):247-59.
  169. Wu JYW, Ko HC, Lane HY (2016): Personality disorders in female and male college students with internet addiction. Journal of Nervous and Mental Disease. Mar;204(3):221-5
  170. Hung CC, Lin CH, Lane HY (2016): Hypothyroidism may exacerbate valproate-related hyperammonemic delirium. Biomedicine (Taipei). Jun;6(2):12.
  171. Tzang RF, Chang YC, Tsai GE, Lane HY* (2016):Sarcosine treatment for oppositional defiant disorder symptoms of attention deficit hyperactivity disorder children. J Psychopharmacol. Oct;30(10):976-82.
  172. Lin CH, Lin PP, Lin CY, Lin CH, Huang CH, Huang YJ, Lane HY* (2016): Decreased mRNA expression for the two subunits of system xc-, SLC3A2 and SLC7A11, in WBC in patients with schizophrenia: evidence in support of the hypo-glutamatergic hypothesis of schizophrenia. J Psychiatr Res. 22;72:58-63. [*corresponding author]
  173. Lin E, Lane HY* (2017). Machine learning and systems genomics approaches for multi-omics data. Biomark Res. Jan 20;5:2doi: 10.1186/s40364-017-0082-y. [*corresponding author]
  174. Hsu WY, Lane HY, Lin CH (2017): Brexpiprazole for the treatment of schizophrenia. Expert Opinion On Pharmacotherapy 18(2):217-223..
  175. Lin HW, Simonavice CA, Lu CR, Lin WL, Wu PL, Chou CY, Liao CH, Lane HY (2017):Severe hypertriglyceridemia secondary to venlafaxine use in an older adult on dialysis -case report.. BMC Health Serv Res. 2017Apr 13;17(1):272. doi: 10.1186/s12913-017-2195-2.
  176. Ho TJ, Lee CW, Lu ZY, Lane HY, Tsai MH, Ho IK, Huang CL, Chiang YC (2017): Effects of Electroacupuncture on Methamphetamine-Induced Behavioral Changes in Mice.Evid Based Complement Alternat Med. 2017;2017:5642708. doi: 10.1155/2017/5642708. Epub2017 Mar 16.
  177. Lin CH, Lane HY* (2017): Clotiapine Monotherapy in a Patient With Clozapine-Resistant Schizophrenia. J Clin Psychopharmacol. 2017 Jun;37(3):363-364. [*corresponding author]
  178. Lin CH, Lane HY* (2017): Bupropion interferes with the image diagnosis of Parkinson’s disease. Neuropsychiatr Dis Treat. 13:2637-2639. doi: 10.2147/NDT.S150912. eCollection 2017.
  179. Chiang YC, Wang RY, Huang CL, Chen SH, Ho WJ, Lane HY, Ho IK, Yang HT, Ma WL (2017): Reduced dosing and liability in methadone maintenance treatment by targeting oestrogen signal for morphine addiction. J Cell Mol Med. 21(12):3552-3564.
  180. Chen YT, Lin CH, Huang CH, Liang WM, Lane HY* (2017): PICK1 Genetic variation and cognitive function in patients with schizophrenia. Sci Rep. 7(1):1889. doi: 10.1038/s41598-017-01975-y. [*corresponding author]
  181. Huang YJ, Lane HY, Lin CH (2017): New treatment strategies of depression: based on mechanisms related to neuroplasticity. Neural Plast. 2017:4605971. doi: 10.1155/2017/4605971. Epub 2017 Apr 11. Review
  182. Lin CY, Liang SY, Change YC, Ting SY, Kao CL, Wu YH, Tsai GE, Lane HY*(2017): Adjunctive sarcosine plus benzoate improved cognitive and global function in chronic schizophrenia patients with constant clinical symptoms: a randomized, double-blind, placebo-controlled trial. World J Biol Psychiatry 18(5):357-368 [*corresponding author]
  183. Lin CH, Lin E, Lane HY* (2017): Genetic biomarkers on age-related cognitive decline. Front Psychiatry. 2017 Nov 21;8:247. doi: 10.3389/fpsyt.2017.00247. eCollection 2017. Review. [*corresponding author]
  184. Lin CH, Yang HT, Chiu CC, Lane HY * (2017): Blood levels of D-amino acid oxidase vs. D-amino acids in reflecting cognitive aging. Sci Rep. 2017 Nov 1;7(1):14849. doi: 10.1038/s41598-017-13951-7. [*corresponding author]
  185. Chiang YC, Wang RY, Huang CL, Chen SH, Ho WJ, Lane HY, Ho IK, Yang HT, Ma WL (2017): Reduced dosing and liability in methadone maintenance treatment by targeting oestrogen signal for morphine addiction. J Cell Mol Med. 2017 Dec;21(12):3552-3564. doi: 10.1111/jcmm.13266. Epub 2017 Jul 12. PMID: 28699698
  186. Wei IH, Chen KT, Tsai MH, Wu CH, Lane HY, Huang CC (2017): Acute Amino Acid d-Serine Administration, Similar to Ketamine, Produces Antidepressant-like Effects through Identical Mechanisms. J Agric Food Chem. 65(49):10792-10803. doi: 10.1021/acs.jafc.7b04217. Epub 2017 Dec 4
  187. Lin CH, Lin CH, Chang YC, Huang YJ, Chen PW, Yang HT, Lane HY*(2018). Sodium benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a Randomized, double-blind, placebo-controlled trial. Biological Psychiatry 2018 Sep 15;84(6):422-432.[*corresponding author]
  188. Hsu WY, Lane HY, Lin CH (2018): Medications used for cognitive enhancement in patients with schizophrenia, bipolar disorder, Alzheimer’s disease, and Parkinson’s disease. Frontiers in Psychiatry. Apr 4;9:91. doi: 10.3389/fpsyt.2018.00091. eCollection
  189. Chang CH, Lane HY, Lin CH (2018). Brain stimulation in Alzheimer’s disease. Front Psychiatry. 2018May 22;9:201. doi: 10.3389/fpsyt.2018.00201. [Epub ahead of print]
  190. Lin E, Lin CH, Lai YL, Huang CH, Huang YJ, Lane HY* (2018): Combination of G72 genetic variation and G72 protein level to detect schizophrenia: machine learning approaches. Front Psychiatry. 2018 Nov 6;9:566. doi: 10.3389/fpsyt.2018.00566. eCollection 2018 [*corresponding author]
  191. Lin TJ, Ko HC, Wu JY, Oei TP, Lane HY, Chen CH (2019): The Effectiveness of Dialectical Behavior Therapy Skills Training Group vs. Cognitive Therapy Group on Reducing Depression and Suicide Attempts for Borderline Personality Disorder in Taiwan. Arch Suicide Res. Jan-Mar;23(1):82-99
  192. Chang CH, Lane HY, Tseng PT, Chen SC, Liu CY, Lin CH (2019): Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: a systematic review and meta-analysis of double-blind randomised controlled trials. J PsychopharmacolApr;33(4):436-448
  193. Lin CH, Huang MW, Lin CH, Huang CH, Lane HY* (2019): Altered mRNA expressions for N-methyl-D-aspartate receptor-related genes in WBC of patients with major depressive disorder. J Affect Disord 245:1119-1125 [*corresponding author]
  194. Lin CH, Lane HY* (2019): Early identification and intervention of schizophrenia: insight from hypotheses of glutamate dysfunction and oxidative stress. Front Psychiatry Feb 27;10:93. doi: 10.3389/fpsyt.2019.00093. eCollection 2019. [*corresponding author]
  195. Lin CH, Lin CY, Wang HS, Lane HY* (2019): Long-term use of clozapine is protective for bone density in patients with schizophrenia. Sci Rep. 2019 Mar 7;9(1):3895 doi: 10.1038/s41598-019-40691-7 [*corresponding author]
  196. Tseng WT, Yeh JY, Lane HY, Lin CH. Effects of donepezil on cognition and global functioning in patients with delayed encephalopathy after carbon monoxide poisoning – A case series. Psychiatry Clin Neurosci. 2019 Jun;73(6):348. doi: 10.1111/pcn.12841.
  197. Hsieh MT, Lane HY, Lin CH (2019): The role of N-methyl-D-aspartate receptor on late-life depression. International Journal of Gerontology (accepted).
  198. Hsu WY, Chiu CC, Chang CC, Chang TG, Lane HY* (2019): The association between cigarette smoking and obstructive sleep apnea. Tob. Induc. Dis. 17(April):27 DOI: 10.18332/tid/105893 [*corresponding author]
  199. Lin CH, Chen PK, Wang SH, Lane HY* (2019):Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): a randomized, double-blind, placebo-controlled, 6-week trial. J Psychopharmacol May 22:269881119849815. doi: 10.1177/0269881119849815. [Epub ahead of print] [*corresponding author]
  200. Lin CH, Lane HY* (2019): The role of N-methyl-D-aspartate receptor neurotransmission and precision medicine in behavioral and psychological symptoms of dementia. Front Pharmacol 2019 May 22;10:540. doi: 10.3389/fphar.2019.00540. eCollection 2019. Review. [*corresponding author]
  201. Tzang RF, Chang CH, Chang YC, Lane HY* (2019): Autism associated with anti-NMDAR encephalitis: glutamate-related therapy. Front Psychiatry doi: 10.3389/fpsyt.2019.00440. [*corresponding author]

Book Chapter:

  1. Chang T, Lane HY, Tsai GE: Glutamate and schizophrenia. In: Glutamate: Function, Regulation and Disorders. Nova Science Publishers, NY, 2012
  2. Chang T, Lane HY, Tsai GE: N-methyl-D-Aspartate enhancing agents: a new class of novel antipsychotic drugs. In: Advances in Psychology Research. Nova Science Publishers, NY, 2013.
  3. Lu M, Lane HY: Clinically Significant Interactions with Antipsychotics. In: Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Adis, NY, 2016.

Patent:

  1. USA Patent Application entitled “Compositions and methods for diagnosis of schizophrenia”, Filing No.: CFP-025517
  2. Taiwan Patent entitled “Compositions and methods for diagnosis of schizophrenia”, Patent No.: I452140 (2014/09/11~2032/11/21)
  3. Taiwan Patent Application entitled “Use of benzoic acid salt in the manufacture of a pharmaceutical composition for treating dementia or mild cognitive impairment”, Patent No.: I573588 (2017/03/11~2034/03/23).
  4. USA Patent Application entitled “Benzoates for use in treating dementia”, Filing No.: 61955521
  5. Japan Patent Application entitled “Use of benzoic acid salt in the manufacture of a composition for prevention or treatment of dementia or mild cognitive impairment”, Filing No.: 特願2017-144263 (approval date: 2019/5/27)
  6. Germany Patent entitled “Use of benzoic acid salt in the manufacture of a composition for prevention or treatment of dementia or mild cognitive impairment”, Patent No.: 21 2014 000 063 (2014/03/24~2024/03/24).
  7. Singapore Patent Application entitled “Use of benzoic acid salt in the manufacture of a composition for prevention or treatment of dementia or mild cognitive impairment”, Filing No.: 11201507188Q.
  8. Canada Patent Application entitled “Use of benzoic acid salt in the manufacture of a composition for prevention or treatment of dementia or mild cognitive impairment”, Patent No.: CA 02902498 (2017/01/23~).
  9. Australia Patent Application entitled “Use of benzoic acid salt in the manufacture of a composition for prevention or treatment of dementia or mild cognitive impairment”, Patent No.: 2014386718. (2017/07/10~twenty years )
  10. Korea Patent Application entitled “Use of benzoic acid salt in the manufacture of a composition for prevention or treatment of dementia or mild cognitive impairment”, Filing No.: 2016-7003184.
  11. Thailand Patent Application entitled “Use of benzoic acid salt in the manufacture of a composition for prevention or treatment of dementia or mild cognitive impairment”, Filing No.: 1601002841.
  12. Turkey Patent Application entitled “Use of benzoic acid salt in the manufacture of a composition for prevention or treatment of dementia or mild cognitive impairment”, Filing No.: 2015/12039.
  13. Taiwan Patent Application entitled “Use of pharmaceutical composition for manufacturing drug of treating betel quid use disorder”, Patent No.: I59937 (2017/09/21~2036/03/01).
  14. USA Patent Application entitled “benzoate for use in preventing or treating anti-N-Methyl-D-Aspartate receptor encephalitis, USPTO Application Number: 62698558
  15. Taiwan Patent Application entitled “Method and kit for diagnosing Alzheimer’s disease using G72 Protein and SLC7A11 mRNA as biomarkers”, Application No.: P10435-TW.
  16. China Patent Application entitled “Method and kit for diagnosing Alzheimer’s disease using G72 Protein and SLC7A11 mRNA as biomarkers”, Application No.: P10435-CN.
  17. USA Patent Application entitled “Method and kit for diagnosing Alzheimer’s disease using G72 Protein and SLC7A11 mRNA as biomarkers”, Application No.: P10435-US.
  18. EU Patent Application entitled “Method and kit for diagnosing Alzheimer’s disease using G72 Protein and SLC7A11 mRNA as biomarkers”, Application No.: P10435-EP.

Technology Transfer:

  1. Sodium benzoate used in mild cognitive impairment and early phase dementia. Excelsior Biopharma Inc. (2016.12 – 2036.12)